Candel Therapeutics, Inc. (CADL): Price and Financial Metrics

Candel Therapeutics, Inc. (CADL): $4.25

0.47 (+12.43%)

POWR Rating

Component Grades













Add CADL to Watchlist
Sign Up

Industry: Biotech



in industry

CADL Stock Price Chart Interactive Chart >

Price chart for CADL

CADL Price/Volume Stats

Current price $4.25 52-week high $14.78
Prev. close $3.78 52-week low $3.02
Day low $3.63 Volume 7,800
Day high $4.25 Avg. volume 46,658
50-day MA $4.33 Dividend yield N/A
200-day MA $6.95 Market Cap 121.95M

Candel Therapeutics, Inc. (CADL) Company Bio

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.

CADL Latest News Stream

Event/Time News Detail
Loading, please wait...

CADL Latest Social Stream

Loading social stream, please wait...

View Full CADL Social Stream

Latest CADL News From Around the Web

Below are the latest news stories about Candel Therapeutics Inc that investors may wish to consider to help them evaluate CADL as an investment opportunity.

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the company’s Chief Scientific Officer. Dr. Barone brings more than 20 years of experience in immunology, experimental medicine, and innovative drug development to help bring important new therapeutics to the clinic. Dr. Barone was previous

Yahoo | February 3, 2022

What Percentage Of Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Do Insiders Own?

If you want to know who really controls Candel Therapeutics, Inc. ( NASDAQ:CADL ), then you'll have to look at the...

Yahoo | January 25, 2022

Candel Therapeutics to Present at Two Upcoming Investor Conferences

NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January: H.C. Wainwright BioConnect ConferenceFormat: Pre-recorded corporate presentationDate/Time: January 10, 2022, on-demand

Yahoo | January 5, 2022

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

LOS ANGELES and NEEDHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality, and Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a strategic collaboration to investigate the use of Bionauts remote-controlled microscale robots for precision delivery of Candels oncolytic viral immunotherapy agents to specific brain tumors.

Intrado Digital Media | December 15, 2021

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor response to initial checkpoint inhibitor therapyCollaboration may identify early markers of response and inform patient selection for treatment NEEDHAM, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage bi

Yahoo | December 10, 2021

Read More 'CADL' Stories Here

CADL Price Returns

1-mo 18.72%
3-mo 3.16%
6-mo -58.98%
1-year N/A
3-year N/A
5-year N/A
YTD -45.65%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5307 seconds.